Emergency Department Outcomes for Patients With Opioid Use Disorder

NCT ID: NCT04289363

Last Updated: 2023-07-06

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 53 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-11-25
• Study Completion Date: 2022-02-18

Brief Summary

Using mixed methods and triangulating multiples sources of data collected over the course of the parent (CTN-0079 - NCT03544112) and the ancillary studies to evaluate the feasibility, acceptability, sustainability and impact of the emergency department (ED)-initiated Buprenorphine (BUP) clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness.

Detailed Description

The ancillary study will use mixed-methods combining quantitative and qualitative inquiry (interview/focus group and field notes) with administrative and health record data with some analyses including data collected from the parent CTN-0079 (NCT03544112) study. Further, qualitative data will be analyzed in the context of themes derived from CTN-0069 (NCT03023930) and CTN-0079. CTN-0079-A1 is planned to be conducted at two of the three sites of the parent study: (1) Catholic Medical Center, Manchester, New Hampshire; (2) Bellevue/NYU Health and Hospitals, New York, NY. Many of the methods, operating procedures, measures and forms will be retained or adapted from the parent study. However, CTN-0079-A1 is a new study in which lessons learned through the parent study have informed important design modifications necessary to improve study rigor and utility.

As in the parent study, CTN-0079, all clinical care (BUP and referral) will be delivered as part of each facility's clinical protocol, rather than as a research procedure. Implementation Facilitation (IF) activities will continue during ancillary trial preparation with a more intensive booster of IF activities occurring in the last month prior to trial commencement. Thereafter, all study IF support will cease and ancillary study data collection will begin. Data collection will occur over a course of approximately 12 months, divided into two 6-month study periods - the Post-IF and Maintenance Periods. A period of at least 6 months should separate the beginning of the Maintenance Period from the time of last study intervention.

Conditions

Opioid-use Disorder

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

ED patients

Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc.

Clinical program implementation

Intervention Type: BEHAVIORAL

Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.

Interventions

Clinical program implementation

Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

Qualitative Population:

• Key stakeholder or opinion leader for ED-initiated BUP
• 18 years of age or older

Full Study Population & Limited Study Population:

• Be able to speak English sufficiently to understand study procedures
• Be a potential candidate for ED-initiated BUP by meeting either of the 2 criteria:

1. Clinical determination: patient is a willing and eligible candidate for ED-initiated BUP or for whom this can be reasonably inferred, including any patient who is administered and/or prescribed BUP as part of the index ED visit.

2. Research determination: Both a and b below must be true at the time of study enrollment:

a) Assessment conducted by an RA indicates that the patient- (all must be true): i. has had nonmedical opioid use within the last 7 days, ii. meets DSM-5 criteria for moderate or severe opioid use disorder (OUD), iii. denies methadone use within 72 hours of ED visit registration, iv. is not engaged in formal medications for opioid use disorder (MOUD) treatment, v. is not prescribed opioids for chronic pain management, vi. reports being interested or "not sure" if interested in receiving BUP as elicited on the ED Health Survey during the index ED visit.

b) Absence of clinical documentation associated with the ED visit indicating that the patient is not a candidate for ED-initiated BUP.

Exclusion Criteria

Qualitative Population:

• Unwilling or unable to provide consent
• currently in jail, prison, or any inpatient overnight facility

Full Study Population:

• Unwilling or unable to provide written/electronic informed consent
• Currently engaged in formal MOUD treatment at the time of index ED visit
• Currently in jail, prison or any inpatient overnight facility as required by court of law
• Previous participation as a patient- participant in CTN-0079 or previous participation as a Full Study participant in the current study
• Presents from a medical-based extended care facility
• Current research participant in a substance use intervention study
• Inadequate locator information (unable or unwilling to provide 2 unique means of contact)
• Unable or unwilling to complete research visits at baseline and Day 30.

Limited Study Population:

• Unwilling or unable to provide written/electronic informed consent
• Currently engaged in formal MOUD treatment at the time of index ED visit
• Currently in jail, prison or any inpatient overnight facility as required by court of law
• Previous participation in the current study as a Limited study or Full study participant
• Presents from a medical-based extended care facility

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role: collaborator

NYU Langone Health

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ryan McCormack, MD, MS

Role: PRINCIPAL_INVESTIGATOR

NYU Langone Health

Locations

Catholic Medical Center

Manchester, New Hampshire, United States

Bellevue Hospital Center

New York, New York, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

3UG1DA013035-18S3

Identifier Type: NIH

Identifier Source: secondary_id

View Link

19-01444

Identifier Type: -

Identifier Source: org_study_id